Dimension Therapeutics, a Cambridge, MA-based gene therapy company focused on developing novel treatments for rare diseases, closed a $30m financing.
New investor OrbiMed joined existing investor Fidelity Biosciences in the round.
Launched in 2013 by Fidelity Biosciences and REGENX Biosciences, and led by Thomas R. Beck, M.D., Founder and Interim Chief Executive Officer, Dimension Therapeutics focused on advancing a platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a product engine for adeno-associated virus (AAV) therapeutics across a wide array of single-gene rare diseases.
The company is hiring.
FinSMEs
23/06/2014